CreativeOne Wealth LLC Lowers Holdings in Zoetis Inc. $ZTS

CreativeOne Wealth LLC trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 38.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,723 shares of the company’s stock after selling 6,091 shares during the period. CreativeOne Wealth LLC’s holdings in Zoetis were worth $1,423,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of ZTS. Vanguard Group Inc. grew its stake in shares of Zoetis by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock worth $6,190,326,000 after purchasing an additional 419,777 shares during the period. Geode Capital Management LLC lifted its stake in shares of Zoetis by 0.9% in the 2nd quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after purchasing an additional 95,294 shares during the period. Norges Bank purchased a new stake in Zoetis during the second quarter worth $809,491,000. Brown Advisory Inc. boosted its holdings in Zoetis by 5.7% during the second quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock worth $726,629,000 after buying an additional 250,829 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Zoetis by 14.6% during the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock valued at $631,046,000 after buying an additional 550,859 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ZTS shares. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a report on Tuesday. Piper Sandler reissued a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. HSBC set a $140.00 target price on Zoetis in a research report on Wednesday, December 10th. Morgan Stanley set a $160.00 price target on Zoetis in a report on Thursday, December 18th. Finally, William Blair reissued an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Zoetis has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Stock Performance

ZTS opened at $120.52 on Wednesday. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The company has a market cap of $50.87 billion, a price-to-earnings ratio of 20.02, a PEG ratio of 1.87 and a beta of 0.95. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $172.23. The firm’s fifty day simple moving average is $125.87 and its two-hundred day simple moving average is $132.39.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same quarter last year, the business earned $1.40 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.